RELYGEN® - Recombinant Human Erythropoietin (rhEPO)2000IU/3000IU/4000IU/5000IU/10000IU
Benefits
- Erythropoietin is a kind of glycoprotein that can promote the erythropoiesis and is mainly produced in the kidney.
- The major biological function of Erythropoietin is to stimulate the growth and differentiation of erythroid progenitor cells at all levels, and ultimately to accelerate the erythropoiesis.
- RELYGEN® is an injectable recombinant human erythropoietin (rhEPO) and mainly used in the prevention and treatment for chronic renal failure, tumor, or anemia caused by radiation.
- RELYGEN® is developed and manufactured by DNA recombinant technology and modern chromatographic separation technology, the engineered cells are constructed with high expression of erythropoietin.
- Quality specification meets requirements of BP/EP. Multi-strengths are more suitable for personalized clinical treatment
Documented bioequivalence
RELYGEN® in comparison withEprex®
Completely Non-clinical and clinical studies demonstrate the clinical efficiency reached 96.2%.
RELYGEN® in comparison withEprex®
Completely Non-clinical and clinical studies demonstrate the clinical efficiency reached 96.2%.